Capricor Therapeutics Inc (CAPR) was Resumed by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $13. H.C. Wainwright advised their investors in a research report released on Jul 6, 2016.
Many Wall Street Analysts have commented on Capricor Therapeutics Inc. Capricor Therapeutics Inc was Initiated by ROTH Capital to “Buy” on Jun 15, 2016.
Capricor Therapeutics Inc opened for trading at $4 and hit $4.0888 on the upside on Friday, eventually ending the session at $3.96, with a gain of 0.25% or 0.01 points. The heightened volatility saw the trading volume jump to 25,429 shares. Company has a market cap of $71 M.
In a different news, on Mar 21, 2016, Linda Marban (CEO) purchased 10,152 shares at $2.40 per share price. According to the SEC, on Mar 21, 2016, Anthony Bergmann (Vice President of Finance) purchased 2,030 shares at $2.40 per share price. On Aug 21, 2015, Louis J Grasmick (director) purchased 11,900 shares at $4.15 per share price, according to the Form-4 filing with the securities and exchange commission.
Capricor Therapeutics Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development which include CAP-1002 CAP-1001 CSps Exosomes Cenderitide (CD-NP) and CU-NP. The Company’s technology is based in cardiospheres (CSps) which are multi-cell clusters of cardiac derived cells. The Company’s product candidate the cardiosphere-derived cells (CDC) is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).